Walleye Capital
IMCR icon

Walleye Capital’s Immunocore IMCR Stock Holding History

Walleye Capital’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,500
Closed -$84.7K – 5551
2024
Q2 		$84.7K Buy
2,500
+100
+4% +$5.1K ﹤0.01% 4786
2024
Q1 		$156K Sell
2,400
-2,100
-47% -$144K ﹤0.01% 4132
2023
Q4 		$307K Buy
4,500
+2,300
+105% +$120K ﹤0.01% 3356
2023
Q3 		$114K Buy
+2,200
New +$130K ﹤0.01% 3883

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Walleye Capital's IMCR Position: Q3 2024 in Review

Walleye Capital sold out of Immunocore (IMCR) in Q3 2024, closing a stake of 89,208 shares — an estimated $3.02M sold.

Walleye Capital first reported a position in IMCR in Q1 2024 and held it in 2 quarters. The position peaked at $3.02M in Q2 2024. 130 funds tracked by Wall St. Rank hold IMCR as of Q3 2024.

  • Walleye Capital reported no remaining Immunocore position as of Q3 2024 after selling out during the quarter.
  • Walleye Capital sold 89,208 Immunocore shares in Q3 2024, an estimated $3.02M.
  • Walleye Capital first reported a position in Immunocore in Q1 2024 and held it in 2 quarters.
  • Walleye Capital's Immunocore position peaked at $3.02M in Q2 2024.
  • 130 funds tracked by Wall St. Rank held Immunocore as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.